Direct IL-17 inhibition with monoclonal antibodies in patients with psoriasis or psoriatic arthritis has been shown to increase the risk of candida infections; similarly, the reactivation of latent tuberculosis infection was observed in patients treated with TNF-inhibitors [64,65]. This evidence concerns the gene IL17A and psoriasis.